Maravai LifeSciences Holdings, Inc. (MRVI) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2023
Loading P/E history...
MRVI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at a price-to-earnings ratio of -16.4x, with a stock price of $3.94 and trailing twelve-month earnings per share of $-0.90.
The current P/E is 188% below its 5-year average of 18.7x. Over the past five years, MRVI's P/E has ranged from a low of 3.7x to a high of 36.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, MRVI trades at a 174% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, MRVI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRVI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MRVI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 127.0 | - | +207%Best | |
| $21B | 25.5Lowest | 6.01Best | +171% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
MRVI Historical P/E Data (2020–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $10.00 | $0.55 | 18.1x | -3% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $12.43 | $1.36 | 9.1x | -51% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $14.01 | $2.69 | 5.2x | -72% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $14.31 | $3.90 | 3.7x | -80% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $25.53 | $3.66 | 7.0x | -63% |
| FY2022 Q2 | $28.41 | $3.34 | 8.5x | -54% | |
| FY2022 Q1 | $35.27 | $2.50 | 14.1x | -24% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $41.90 | $1.54 | 27.2x | +46% |
| FY2021 Q3 | $49.08 | $1.34 | 36.6x | +96% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $41.73 | $1.34 | 31.1x | +67% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $35.64 | $1.16 | 30.7x | +65% |
| FY2020 Q4 | $28.05 | $0.86 | 32.5x | +74% |
Average P/E for displayed period: 18.7x
See MRVI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRVI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRVI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRVI — Frequently Asked Questions
Quick answers to the most common questions about buying MRVI stock.
Is MRVI stock overvalued or undervalued?
MRVI trades at -16.4x P/E, below its 5-year average of 18.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MRVI's valuation compare to peers?
Maravai LifeSciences Holdings, Inc. P/E of -16.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is MRVI's PEG ratio?
MRVI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2023.